| No. |
DrugBank |
Drug (Description in trials)
[Number of descriptions] |
KEGG DRUG * | KEGG GENES *
[Number of genes] |
KEGG PATHWAY
[Number of pathways] |
Disease ID *
[Number of diseases] |
| 1 | Aflibercept | [1] Aflibercept; | D09574 |
[3] PGF, VEGFA, VEGFB |
[21] AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
[2] 90, 166 |
| 2 | Lansoprazole | [4] Lansoprazole; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms; | D00355 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[6] 63, 71, 98, 166, 222, 299 |
| 3 | Magnesium | [16] (s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; (s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; Magnesium; Magnesium citrate; Magnesium gluconate; Magnesium hydroxide; Magnesium oxide; Magnesium sulfate; Mineral boost (magnesium); Nexium (esomeprazole magnesium); Omeprazole magnesium; Saroglitazar magnesium 2 mg; Saroglitazar magnesium 4 mg; Sodium picosulfate, magnesium oxide and citric acid; Sodium picosulfate/magnesium citrate laxative; Sulfate, magnesium; | - |
- |
- |
[15] 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
| 4 | Magnesium oxide | [2] Magnesium oxide; Sodium picosulfate, magnesium oxide and citric acid; | D01167 |
- |
- |
[3] 6, 166, 291 |
| 5 | Ranibizumab | [3] Intravitreal injection ranibizumab; Ranibizumab; Ranibizumab injection (0.5 mg); | D05697 |
[1] VEGFA |
[21] AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
[4] 34, 166, 227, 301 |